Coherus Oncology, Inc.
Coherus Oncology, Inc.（CHRS）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · CHRS · 截至 2025年9月30日
股东结构概览
121
机构持有人数
▲ 5 vs Q2
$84.72M
机构持仓总市值
▲ $44.28M vs Q2
122.41M
总流通股
freeFloat 94.87%
51.67M
13F 申报持股数
▼ 3.69M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
CHRS 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 10.46M | 9.01% | 9.01% | $17.15B | Nov 12, 2025 | ▼ 279.7K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 10.32M | 8.89% | 8.89% | $16.93B | Nov 7, 2025 | ▼ 249.4K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 5.10M | 4.39% | 4.39% | $8.36B | Nov 14, 2025 | — held |
KOHLBERG KRAVIS ROBERTS & CO. L.P. biological products, (no diagnostic substances) | 3.04M | 2.62% | 2.62% | $4.93B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.74M | 2.36% | 2.36% | $4.50B | Nov 12, 2025 | ▲ 64.8K |
STATE STREET CORP biological products, (no diagnostic substances) | 2.22M | 1.92% | 1.92% | $3.65B | Nov 14, 2025 | ▲ 4.8K |
CM MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.10M | 1.81% | 1.81% | $3.44B | Nov 13, 2025 | ▼ 150.0K |
C WORLDWIDE GROUP HOLDING A/S biological products, (no diagnostic substances) | 1.93M | 1.66% | 1.66% | $3.16B | Nov 5, 2025 | — held |
PANAGORA ASSET MANAGEMENT INC biological products, (no diagnostic substances) | 1.38M | 1.19% | 1.19% | $2.26B | Nov 13, 2025 | ▲ 581.6K |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC biological products, (no diagnostic substances) | 993.1K | 85.55% | 85.55% | $1.63B | Nov 10, 2025 | ▲ 11.7K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
26
增持
+2.01M 股2
新建仓
首次建仓14
减持
−1.86M 股0
清仓
完全退出净股数变化（前50家）
+150.7K
+2.01M / −1.86M
净新增持仓人
+14
新建 2 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
CHRS 内幕交易记录
数据来源：SEC Form 4
0
买入笔数
2
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
McMichael Bryan J Chief Financial Officer | May 29, 2026 | Award | 100,000 | $1.59 | $159.0K | 100.0K | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | Award | 30,000 | $1.59 | $47.7K | 30.0K | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | Award | 25,000 | $1.59 | $39.8K | 25.0K | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | Award | 15,000 | $1.59 | $23.9K | 15.0K | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 100,000 | $14.76 | $1.48M | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 25,000 | $14.67 | $366.8K | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 15,000 | $10.78 | $161.7K | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 25,000 | $9.87 | $246.7K | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 25,000 | $6.00 | $150.0K | 0 | Form 4 ↗ |
McMichael Bryan J Chief Financial Officer | May 29, 2026 | D-Return | 30,000 | $5.44 | $163.2K | 0 | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Coherus Oncology, Inc.（CHRS）主要由机构投资者持有，机构持股比例约为 42.2%。公司内部人员持股约 5.13%，散户及公众持股约占剩余的 52.65%。
Coherus Oncology, Inc. 最大机构股东为 BLACKROCK, INC.，截至 September 30, 2025 持有约 10.46 million 股，占总流通股的 9.01%。
目前共有 121 家机构持有 CHRS 股票，合计持仓市值约 $84,724,926，数据来源为最新 SEC 13F 申报。
常见问题
CHRS ownershipCoherus Oncology, Inc.（CHRS）主要由机构投资者持有，机构持股约 42.2%。最大股东为 BLACKROCK, INC.，持股比例 9.01%。内部人员持股约 5.13%。数据来源 SEC Form 13F，截至 September 30, 2025。